OBEZİTE VE KARACİĞER PATOLOJİSİ
Synopsis
This text comprehensively examines obesity-related liver pathologies, including their historical background, etiology, diagnosis, staging, and treatment methods. Driven by improved socioeconomic conditions and sedentary lifestyles, obesity has become increasingly common across all age groups, serving as a major cause of morbidity and mortality. Non-alcoholic fatty liver disease (NAFLD), which represents the hepatic manifestation of obesity and metabolic syndrome, encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Multiple factors contribute to its etiology, such as insulin resistance, type 2 diabetes, visceral adiposity, genetic predisposition, smoking, and poor dietary habits. Liver biopsy remains the most reliable diagnostic method, utilizing scoring systems like the NAS score or the FLIP algorithm (SAF score) to evaluate steatosis, ballooning degeneration, and lobular inflammation. Differential diagnosis requires ruling out alcoholic liver disease, drug-induced liver injury, and HCV infection. Although pharmacological agents like vitamin E and bariatric surgery options are evaluated, the most effective core treatment remains lifestyle modification and weight loss.
References
Aster VKAAJ. Robbins Basic Pathology. Aster VKAAJ, editor: Elsevier; 2017.
Suriawinata A, Fiel MI. Liver pathology in obesity. Seminars in liver disease. 2004;24(4):363-70.
Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva endocrinologica. 2017;42(2):92-108.
Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clinics in liver disease. 2007;11(1):17-23, vii.
Myers JGLLJMJ. Rosai and Ackerman's Surgical Pathology. 11th Edition ed. Myers JGLLJMJ, editor: Elsevier; 2017. 2306 p.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American journal of gastroenterology. 1999;94(9):2467-74.
Kleiner D, Brunt E, Van Natta Mf, Behling C, Contos M, Cummings O, et al. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2005;41(6):1313-21.
Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings OW, et al. 160 Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology (Baltimore, Md). 2003(38):233.
GÜLLÜOĞLU M. Nonalkolik Yağlı Karaciğer Hastalığında Histopatolojik Değerlendirme. Turkiye Klinikleri J Med Pathol. 2017;2(1).
Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nature reviews Disease primers. 2015;1:15080.
Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World journal of hepatology. 2017;9(16):715-32.
Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015;47(12):997-1006.
Nanda K. Non-alcoholic steatohepatitis in children. Pediatric transplantation. 2004;8(6):613-8.
Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Human reproduction (Oxford, England). 2016;31(6):1347-53.
Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. 2015;2015:815721.
Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in liver disease. 2015;35(3):270-90.
Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. Immunology. 2018;155(4):407-17.
van der Heijden RA, Sheedfar F, Morrison MC, Hommelberg PP, Kor D, Kloosterhuis NJ, et al. High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. Aging. 2015;7(4):256-68.
Brunt EM. Pathology of fatty liver disease. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2007;20 Suppl 1:S40-8.
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology (Baltimore, Md). 2015;62(5):1417-32.
Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clinics in liver disease. 2016;20(2):215-24.
Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology (Baltimore, Md). 2012;56(5):1751-9.
Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2014;60(2):565-75.
Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clinics in liver disease. 2016;20(2):293-312.
Allard J, Le Guillou D, Begriche K, Fromenty B. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Advances in pharmacology (San Diego, Calif). 2019;85:75-107.
Han ML, Lee WJ. Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis C Viral Infection. Obesity surgery. 2019;29(3):828-34.
Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2004;19(5):537-44.
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. The American journal of gastroenterology. 2003;98(11):2485-90.
JANSEN PM. Nonalcoholic steatohepatitis. Netherlands journal of medicine. 2004;62(7):217-24.
Mahawar KK, Parmar C, Graham Y, Abouleid A, Carr WR, Jennings N, et al. Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base. Obesity surgery. 2016;26(1):177-81.